On 12 Nov 2026 DaVita closed at $174.07, +53.2% this year; market cap $11.40bn, P/E 12.4.
Health Care · Health Care Services · NYSE · United States
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
| Market cap | $11.40bn |
| P/E (trailing) | 12.4 |
| EPS (TTM) | $14.05 |
| Beta | 0.86 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 29 Oct 2026 |
| Next earnings | 25 Jan 2027 |
| YTD | +53.2% |
| 1Y | +40.8% |
| 3Y | +25.4% |
| 5Y | +10.5% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $13.64bn | $746.80m | $1.31bn |
| 2024 | $12.82bn | $936.34m | $1.47bn |
| 2023 | $12.14bn | $691.53m | $1.49bn |
| 2022 | $11.61bn | $560.40m | $961.14m |
| 2021 | $11.62bn | $978.45m | $1.29bn |
We publish no single base value for DaVita. Our valuation methods put it between $156.78 and $365.08 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.